Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 1.00 |
| ▸ | CHAT | P28329 | 2/20 | 0.87 |
| ▸ | EP300 | Q09472 | 3/20 | 0.86 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.86 |
| ▸ | AURKA | O14965 | 2/20 | 0.86 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.86 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29761309 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL4356277 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL29518048 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL6086 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL17656841 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL31126614 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL822955 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL19018640 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL14593550 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL29761307 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11026426-B2 | Oxadiazole and phenol derivatives as antibacterial and/or herbicidal agents | NORTHERN ILLINOIS RESEARCH FOUNDATION (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3679065-A1 | SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR) | California Institute of Technology (US) | 2020-07-15 | — | — | EP | disclosed |
| CN-106244615-B | Engineering bacterium, construction method thereof and application of engineering bacterium in preparation of geraniol | 天津大学 | 2020-05-15 | — | — | CN | disclosed |
| CN-105950493-B | Engineering bacterium, construction method thereof and application of engineering bacterium in preparation of crocetin | 天津大学 | 2019-12-27 | — | — | CN | disclosed |
| WO-2019051001-A1 | SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR) | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20160169909-A1 | COMPOSITION CONTAINING PYRUVATE DEHYDROGENASE KINASE INHIBITOR FOR TREATING CHRONIC INFLAMMATORY PAIN | KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL (KR) | 2016-06-16 | — | — | US | disclosed |
| US-20110300595-A1 | MICROORGANISM FOR PRODUCING SUCCINIC ACID | ORGANO BALANCE GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11026426-B2 | Oxadiazole and phenol derivatives as antibacterial and/or herbicidal agents | CBR3, AOC3, AHR | NAA50 1373/4885CHAT 398/4885EP300 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.